Psilocybin Dispensaries and Online Health Claims in Canada
Jenna Matsukubo, Sarah Dickson, Jennifer Xiao, Erik Loewen Friesen, Marco Solmi, Benedikt Fischer, Jess G. Fiedorowicz, Daniel T. Myran
JAMA Network Open April 1, 2025 DOI: 10.1001/jamanetworkopen.2025.2853 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional study Peer reviewed |
|---|---|
| Population | Psilocybin dispensaries in Canada |
| Topics | Psilocybin |
| Keywords | Dispensary Advertising Product mathematics Environmental health |
| Citations | 7 |
| Key findings | Psilocybin dispensaries in Canada, present in over a third of major cities, made unverified health claims and lacked warnings of potential harms. |
Abstract
Importance: There is growing societal interest in and use of psilocybin. While psilocybin in Canada is illegal outside of clinical trials, there have been anecdotal reports of increasing access via unregulated online purchases and retail dispensaries.
Objective: To describe access to and the characteristics of psilocybin dispensaries across Canada and the health claims and warnings made on dispensary websites. Design, Setting, and Participants This cross-sectional study used systematic web searches and media reports to identify psilocybin dispensaries operating in Canada in May 2024. Data analysis was performed from June 17 to August 29, 2024.
Main Outcomes and Measures: Descriptive and geospatial analyses were used to identify the psilocybin dispensary characteristics, product types, and store distribution. Content analysis assessed the nature and frequency of health claims and warnings on websites.
Results: As of May 2024, 57 psilocybin dispensaries were identified in Canada (0.18 dispensaries per 100 000 individuals aged ≥15 years) in 15 of Canada’s 42 major urban cities (35.7%). Approximately 815 628 (2.6%) of Canadians lived within 1 km of a dispensary. Only 4 of 13 provinces and territories had a dispensary, with most in Ontario and British Columbia. Of the 57 stores, 35 (61.4%) were part of a chain (≥2 stores owned by a single company) and 52 (91.2%) had an online presence. Stores sold a wide variety of products, including dried mushrooms (100.0%), microdosing capsules (97.8%), psilocybin-infused chocolate (91.3%) and gummies (93.4%), and most stores (65.2%) sold products mimicking popular food brands. Among stores with websites, 86.4% claimed mental health benefits of psilocybin (eg, alleviating anxiety). While 86.4% of websites provided health warnings, relevant warnings, such as those about use while driving (9.1%), during pregnancy (13.6%), or in individuals with a history of psychosis, schizophrenia, or bipolar disorder (31.8%) were rare. Conclusions and Relevance In this study, psilocybin retailers, who were present in over a third of major Canadian cities, made a variety of unverified health claims and lacked warnings of potential harms, suggesting the need for greater regulatory measures to protect the public.
Comparable studies
Other cross-sectional and survey studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... | 2016 | Cross-sectional survey | n = 1,993 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... | 2019 | Cross-sectional survey | n = 343 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
Citations in the library
Cited by 7
- Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution Canadian Journal of Public Health March 19, 2026
- Psychedelic therapy and cultural humility Translational Psychiatry February 27, 2026
- Psychedelics stores, their regulation and public health: knowledge, perceptions, attitudes and opinions of Canadians. International Journal of Drug Policy July 9, 2026
- Psychedelics: Future Therapeutics in Major Depression? Advances in experimental medicine and biology 2026
- Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review. JAMA Network Open October 1, 2026
and 2 more in the library
Cites 22
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Journal of Psychopharmacology March 8, 2012
and 17 more in the library